Emerging agents targeting triglycerides

Keyphrases

• Triglycerides 100%
• Triglyceride-rich Lipoproteins 100%
• Lipoprotein Metabolism 100%
• Emerging Agents 100%
• Fibroblast Growth Factor 21 (FGF21) 66%
• Chylomicronemia 66%
• Triglyceride Level 33%
• Cardiovascular Risk 33%
• Type 2 Diabetes Mellitus (T2DM) 33%
• Insulin Resistance 33%
• Atherosclerotic Cardiovascular Disease (ASCVD) 33%
• Mixed Hyperlipidemia 33%
• Omega-3 Fatty Acids 33%
• Atherogenic Lipoproteins 33%
• Fibrates 33%
• Pancreatitis 33%
• Significant Benefit 33%
• Disease Spectrum 33%
• Traditional Therapy 33%
• Lipoprotein Lipase 33%
• NewHope 33%
• Biochemical Pathways 33%
• Liver Type 33%
• Emerging Therapies 33%
• Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) 33%
• Diverse Condition 33%
• Favorable Effect 33%
• Apolipoprotein B (apo B) 33%
• Apolipoprotein C-III (ApoC-III) 33%

Medicine and Dentistry

• Triacylglycerol 100%
• Lipoprotein Metabolism 100%
• Triglyceride-Rich Lipoprotein 100%
• FGF21 66%
• Synapsin II 66%
• Hyperlipidemia 33%
• Maturity Onset Diabetes of the Young 33%
• Liver Disease 33%
• Cardiovascular Risk 33%
• Insulin Resistance 33%
• Pancreatitis 33%
• Hope 33%
• Lipoprotein 33%
• Morbidity 33%
• Omega-3 Fatty Acid 33%
• Lipoprotein Lipase 33%
• Apolipoprotein C3 33%
• Chylomicronemia 33%
• Diseases 33%
• Arteriosclerotic Heart Disease 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Triacylglycerol 100%
• Lipoprotein 66%
• Fibroblast Growth Factor 21 33%
• Synapsin II 33%
• Hyperlipidemia 16%
• Syndrome 16%
• Liver Disease 16%
• Cardiovascular Risk 16%
• Insulin Resistance 16%
• Omega-3 Fatty Acid 16%
• Fibric Acid Derivative 16%
• Pancreatitis 16%
• Coronary Artery Atherosclerosis 16%
• Morbidity 16%
• Lipoprotein Lipase 16%
• Apolipoprotein C3 16%
• Diseases 16%
• Maturity Onset Diabetes of the Young 16%